Tagged with Biotech

Switzerland Georg Pirmin Meyer, SVP and Head of International at Blueprint Medicines, shares insights into the company’s journey from a promising startup to a fast-scaling biotech leader focused on allergy/inflammation and haematology/oncology. Meyer discusses Blueprint’s innovative approach to international expansion, patient-centric strategy, and ambitious plans for growth in new markets. He…

Switzerland Lars Nieba PhD, CEO of Engimmune, shares insights into the company’s innovative approach to T-cell therapies and its strategic direction as it prepares for its Series A funding round. Nieba discusses the promising therapeutic areas Engimmune is targeting—particularly liver cancer and immunology—and the company’s unique technology that harnesses soluble T-cell…

USA Focused on rare and ultra-rare genetic diseases, Ultragenyx identifies itself as the industry’s most productive company working in the field of high un-met need diseases. With no fewer than four products approved across five indications, a blockbuster therapy that reached 2023 revenues of USD 328 million, and six candidates in…

Switzerland Kari Sarvanto outlines his journey from leading PRIMEX to establishing CRAB, a preclinical oncology company focused on non-toxic cancer treatments. Sarvanto highlights his strategic leadership background, the innovative approach of targeting metabolic dysfunctions in cancer, and the promising progress of their lead drug, CRB091, particularly in treating aggressive cancers like…

Switzerland Swiss Biotech’s Michael Altorfer explains how Switzerland’s biotech industry continues to grow, driven by startups and SMEs and supported by strong international collaborations across the entire value chain. He outlines how Swissmedic’s proactive approach to advanced therapies and participation in the Access Consortium enables faster and more efficient drug approval…

Japan The Japan Exchange Group (JPX) is a key platform for both established companies and emerging bio ventures in Japan. Recently, it has focused on fostering innovation and growth in sectors like biotechnology through its Growth Market segment. This market is specifically designed for early-stage companies, providing them with an avenue…

Hong Kong It has been an extremely challenging couple of years for Hong Kong’s financial sector, including for the wealth of biotech companies listed in the city, but fundamentals remain strong, and the green shoots of recovery are starting to be seen.   While biotech has historically been a high-risk, high-reward sector,…

China Dr George Chen explores D3 Bio’s strategic approach to drug development, its ambition to launch two cancer therapies in the US within five years, and the critical role of partnerships and funding in achieving these goals. Reflecting on this journey, Dr. Chen emphasizes, “It’s a journey to realize a dream…

Global Originally seen as occasional service providers for the pharma industry, contract development and manufacturing organisations (CDMOs) have become vital strategic partners. Helping pharma and biotech companies advance their therapies through their outsourced services, CDMOs have demonstrated their ability to respond to the industry’s shifting priorities as well as its pre-…

China Adept at identifying promising biotechs, Qiming Venture Partners-backed companies saw no less than eight IPOs last year. Managing Partner Nisa Leung provides an update on the firm’s activities in light of current China-US geopolitical tensions and the evolving business development models that have become more focused on licensing innovative drugs…

China Dr James Xue, founder, chairman and CEO of CANbridge Pharmaceuticals shares the career journey that led him to China’s first rare disease-focused company and the role CANbridge is playing in shaping policies relating to rare diseases, such as the National Rare Disease List. Xue also outlines the company’s robust pipeline…

Switzerland Switzerland, home to industry giants like Novartis and Roche, boasts a thriving pharma industry that generates some seven percent of the country’s GDP, as well as a flourishing biotech scene. However, all is not so well in Switzerland’s domestic healthcare landscape, where surging insurance premiums and drug costs mean that…